IXICO PLC announced a 23% increase in revenues and a 38% growth in its order book compared to the previous year, driven by strong demand in Alzheimer's disease clinical trials and new contract wins. The company highlighted its evolving TechBio strategy, supported by a recent £10 million capital raise, aimed at productizing its IXI technology platform while maintaining momentum in its imaging CRO business. IXICO is expanding its presence in neurodegenerative diseases and entering new revenue streams through diagnostics partnerships, with a focus on blood-based biomarkers. The company expects to sustain growth with 95% of its 2026 revenues already visible in its order book.
Uber Technologies Inc. has made a full takeover offer for Delivery Hero at €33 per share, slightly below Delivery Hero's recent closing price. Prior to the offer, Uber increased its stake in Delivery Hero from about 7% to 19.5%, becoming the largest ...
In the past 48 hours, nearly $954 million in crypto long positions were liquidated amid market volatility, yet ZCash (ZEC) maintained a strong bullish trend. The token broke out of a short-term range, supported by steady buying pressure and capital i...
Solana (SOL) is trading around $82, down about 70% from its peak near $295, reflecting weak market demand and significant selling pressure. The critical resistance level at $95 must be surpassed on the weekly chart to trigger a potential relief rally...
Bitcoin dropped to a five-week low of $74,250 before recovering after President Trump announced a largely negotiated peace agreement involving Iran and several Middle Eastern countries. The deal includes reopening the Strait of Hormuz, easing geopoli...
Nasdaq has received approval from the SEC to launch cash-settled Bitcoin index options on the Philadelphia Stock Exchange, using the CME CF Bitcoin Real Time Index as the benchmark. These European-style options settle in cash without actual Bitcoin t...
